ULMA automated packaging solutions boost production levels

 

If Britain is to remain competitive in a global market it needs to improve its productivity and one way of achieving this is by adopting fully automated packaging processes for greater accuracy, to cut waste, save time and money and significantly increase output.

ULMA Packaging, one of the UK’s leading suppliers of packaging machinery and complete production lines, now boasts an automation division to help clients in the food, drinks, pharmaceutical and other related sectors to maximise their packaging solutions.

Completely automated packaging lines can contribute to a thriving manufacturing sector by playing an important role in developing competitiveness by driving productivity and innovation through the supply chain – critical cornerstones to future prosperity for corporates and SMEs alike.

UK companies are realising that automation needn’t cost a fortune and doesn’t have to be complex – yet it can cut manufacturing costs, offer flexibility to accommodate changes in product and demand, improve quality and be environmentally friendly.

ULMA can provide a wide range of high level automated solutions, such as loading, packaging, weighing and labelling, case packing, palletising/depalletising, internal case or tray transport. Centralised line control software has been designed and developed to provide real time control of the packaging line from one single point for any ULMA installation, useful for improving the efficiency and performance of the production line.

At the core of all complete automated lines from ULMA is its renowned range of different packaging machines – Flowrappers, Thermoforming, Tray-sealing, Vertical and Shrink – as well as its world class sales and service support in the UK.

The state-of-the-art range of flowrapping equipment from ULMA is reliable and robust, suitable for a wide range of films that maintain the texture and quality of food items such as ovenable cook-in-the-bag chicken, fresh produce, chocolate, confectionery and biscuits.

ULMA’s new generation of TFS Thermoformers are the most hygienic on the market thanks to an innovative design, which provides easy access for deep cleaning to help food manufacturers meet and even surpass the most exacting regulatory standards demanded by today’s industry. On the tray-sealing front, ULMA offers high speed MAP packing of meat and poultry products along with a high speed vertical wrapper, a packaging machine capable of speeds of up to 140 packs per minute and adaptable to intermittent or continuous mode.

Other automated solutions include high production speed robots to enable individual loading of goods into cavities, trays or feeding belts. The system provides product quality control and only loads the products which fulfil the required quality parameters. A Multiweigher loading system using a weighing and counting multi-combination system, also offers a high accuracy level.

By tapping into the latest packaging technologies, production processes and methods related to automation UK manufacturers can improve the workplace environment, boost productivity and maximise profits to ensure their future sustainability in an increasingly discerning marketplace.

 

 

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...